SecBot SecBot

VOR drug pipeline

Vor Biopharma Inc. · 2 rated drugs
$18.97
−2.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (global); Approved in China (SLE, IgAN, SjD)
Time to marketTelitacicept is already marketed in China for SLE. For US/EU approval, the earliest potential timeline depends on the global Phase 3 UPSTREAM MG readout (1H 2027) followed by BLA submissions, with potential approval possibly in 2028-2029 if results are positive.

telitacicept Updated Nov 13

What to watch

The next major catalyst is the topline readout from the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, expected in the first half of 2027. Positive data would support US/EU regulatory filings and validate Vor Bio's strategy of replicating RemeGen's Chinese clinical success globally. Negative or mixed results would severely damage the thesis, as telitacicept is Vor Bio's lead asset. Also watch for enrollment completion updates from the UPSTREAM SjD Phase 3 trial in Sjogren's disease.

Bull case
  • Telitacicept has already demonstrated strong efficacy across multiple autoimmune indications in China, including NMPA approvals for SLE, IgA nephropathy, and Sjogren's disease, de-risking the mechanism.
  • The global Phase 3 UPSTREAM MG trial is fully enrolled with topline results expected 1H 2027; positive data could unlock a multi-billion-dollar US/EU market opportunity.
  • Vor Bio holds ~$491-514 million in cash (pro-forma), providing runway through early 2029 and fully funding the global Phase 3 program without near-term dilution risk.
Bear case
  • Telitacicept is not yet approved outside China; global regulatory path depends on replicating Chinese Phase 3 results in Vor Bio's own global trials, which carries execution risk.
  • Vertex's povetacicept (a competing dual BAFF/APRIL inhibitor) has an upcoming FDA decision and could establish a competitive lead in the same mechanism class.
  • Vor Bio's original oncology pipeline was deprioritized for this autoimmune pivot; investors are betting on a single drug class with no marketed products yet in ex-China markets.
● neutral
Impact
PhasePreclinical (IND-enabling)
Time to marketRC298 is in IND-enabling (preclinical) development. An IND submission in China is expected in H1 2027. If clinical development proceeds, an approved product would likely be several years away, assuming successful Phase 1, 2, and 3 trials.

RC298 Updated Nov 14

What to watch

Watch for the IND submission for RC298 in China expected H1 2027. Near-term stock movement will likely come from telitacicept Phase 3 readouts (UPSTREAM MG and SjD topline data expected 1H 2027), not RC298. The deal's upfront cost ($10M cash + ~$46M in warrants) and potential future dilution from the $150M ATM facility create an overhang to monitor.

Bull case
  • RC298 is a next-generation, long-acting dual BAFF/APRIL inhibitor designed for higher potency and extended half-life, offering potential best-in-class dosing convenience over first-generation telitacicept in a validated autoimmune mechanism.
  • The deal expands Vor Bio's BAFF/APRIL franchise (already anchored by telitacicept's positive Phase 3 data in IgA nephropathy and myasthenia gravis), creating a potential pipeline-in-a-product strategy.
  • Vor Bio secured exclusive rights to RC298 outside Greater China at a relatively modest upfront ($56M total), with the existing milestone/royalty framework from the original telitacicept deal already in place, suggesting disciplined capital allocation.
Bear case
  • RC298 is in IND-enabling (preclinical) development with no clinical data yet; clinical failure or delays are the primary risk. The program may never reach human studies.
  • The upfront cost to Vor Bio is significant: $10M cash plus a pre-funded warrant for 2.3 million shares at $0.0001/share (valued at ~$46M based on the Nov 11 closing price), creating immediate shareholder dilution.
  • Up to $300M in additional development milestones plus royalties could burden Vor Bio's balance sheet if the program advances, straining its cash runway (though currently into early 2029).